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Abstract The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a
 global pandemic. Vaccine development is no doubt the best long-term immunological approach, but 
in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent 
plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies 
(EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly 
purified F(ab’)2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing 
a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product 
obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our prod-
uct shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent 
plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be 
conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina.  
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Resumen Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina.
 La enfermedad denominada COVID-19 es causada por el coronavirus SARS-CoV-2 y es actualmente 
considerada una pandemia a nivel global. El desarrollo de vacunas es sin duda la mejor estrategia a largo plazo, 
pero debido a la emergencia sanitaria, existe una necesidad urgente de encontrar soluciones rápidas y efectivas 
para el tratamiento de la enfermedad. Hasta la fecha, el uso de plasma de convalecientes es la única inmunoterapia 
disponible para pacientes hospitalizados con COVID-19. El uso de anticuerpos policlonales equinos (EpAbs) es otra 
alternativa terapéutica interesante. La nueva generación de EpAbs incluyen el procesamiento y purificación de los 
mismos y la obtención de fragmentos F(ab’)2 con alta pureza y un excelente perfil de seguridad en humanos. Los 
EpAbs son fáciles de producir, lo cual permite el desarrollo rápido y la elaboración a gran escala de un producto 
terapéutico. En este trabajo mostramos el desarrollo de un suero terapéutico obtenido luego de la inmunización 
de caballos utilizando el receptor-binding domain de la glicoproteína Spike del virus. Nuestro producto mostró ser 
alrededor de 50 veces más potente en ensayos de seroneutralización in vitro que el promedio de los plasmas de 
convalecientes. Estos resultados nos permitirían testear la seguridad y eficacia de nuestro producto en ensayos 
clínicos de fase 2/3 a realizarse a partir de julio de 2020 en la zona metropolitana de Buenos Aires, Argentina.  
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Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), the causative agent of coronavirus dis-
ease 2019 (COVID-19), is currently generating a global 
pandemic with more than 9.3 million infections and 478 
000 fatalities (as of June 23rd, 2020) (https://www.worl-
dometers.info/coronavirus/)1. In Argentina, despite the 
early quarantine introduced by the Argentine government, 
SARS-CoV-2 has caused more than 44 300 infections 
and around 1040 deaths. Immunotherapy appears as 
the most promising therapeutic approach to alleviate the 
burden of this disease. Convalescent plasma is the only 
antibody-based therapy available for COVID-19 patients to 
date. This strategy has proved to be safe and preliminary 
studies showed that plasma transfusion is a potentially 
efficient treatment option for patients hospitalized with 
COVID-19. However, it is not clear whether enough donors 
with adequate levels of antibodies will be available for a 
massive application of this approach. 
Vaccine development is no doubt the best long-term 
immunological approach, but in the current epidemio-
logical and health emergency there is a need for rapid 
and effective solutions. Equine polyclonal antibodies 
(EpAbs) can be one of these interim solutions. EpAbs 
recognize a vast array of epitopes (limiting the risk of 
viral escape mutations) and tend to develop greater 
avidity than monoclonal antibodies (mAbs) for their 
cognate antigens. In addition, EpAbs are easy to 
manufacture allowing a fast development and scaling 
up for human use. While in the past the risk of serum 
sickness −mainly due to the presence of Fc fragments− 
disfavored the use of EpAbs, the new generation of 
processed and purified EpAbs containing highly puri-
fied F(ab’)2 fragments demonstrated to be safe and 
well tolerated. This kind of products has been used for 
decades in the management of clinical emergencies, 
such as snakebite and scorpion sting envenomation, 
severe poisoning (tetanus toxin, digoxin and, more re-
cently, botulinum toxin) and severe infectious diseases 
like avian influenza. Starting in 2015, the Argentine 
biotech startup company Inmunova has developed a 
therapy based on Neutralizing Equine Anti Shiga Toxin 
(NEAST) F(ab´)2 fragment antibodies for the preven-
tion of the hemolytic-uremic syndrome2. The NEAST 
therapy has successfully passed preclinical and phase 
1 analysis, showing an adequate profile of safety and 
pharmacokinetics (unpublished results). A phase 1 
final report was submitted to the Argentinean health 
authority Agency (ANMAT) and its favorable evalua-
tion enabled the initiation of a phase 2/3 clinical trial 
in the pediatric population, which is currently ongoing 
(http://www.clinicaltrials.gov, identifier NCT04132375).
A recent report has shown that the receptor binding 
domain (RBD) from the viral Spike glycoprotein elicits 
high titers of neutralizing antibodies against SARS-CoV-2 
when used as an immunogen in horses3. Based on this 
study, and in the previous experience of Inmunova, at the 
beginning of April 2020 we launched a protocol to produce 
equine hyperimmune sera for the treatment of COVID-19 
patients. In this article, we describe the rapid and efficient 
production of therapeutic hyperimmune sera from which 
we obtained the F(ab´)2 fragment products that will be en-
tering clinical trials in the next weeks. For this purpose, we 
also selected the RBD domain of the SARS-CoV-2 Spike 
protein as an immunogen3, 4 since several recent reports 
indicate that most of the Spike neutralizing epitopes reside 
in this domain5, 6. Structural biology analysis has explained 
this fact at the molecular level. As shown in Figure 1A, the 
contact of the virus with its cellular human receptor, the 
angiotensin converting enzyme 2 (ACE2), is mediated by 
a strong protein-protein interaction between the enzyme 
and the RBD. Thus, antibodies directed against the RBD 
surface are thought to block the viral entry to host cells. 
Recent publications also demonstrated that sera from 
SARS-CoV-2 infected patients show a clear correlation 
between reactivity in enzyme-linked immunosorbent 
assays (ELISA) against RBD and titers obtained in sero-
neutralization assays7, 8. In addition, the use of RBD as 
an immunogen avoids eliciting antibodies against other 
domains of Spike that could have deleterious effects, such 
as antibody dependent enhancement9, 10. 
Recombinant RBD was produced using the mammalian 
expression plasmid pCAGGS, which was kindly provided 
by Prof. Florian Krammer4. This plasmid contains the cod-
ing region for RBD (residues 319 to 541 of Spike) along 
with a signal peptide (residues 1-14) and a C-terminal 
hexahistidine tag. The plasmid was transfected in human 
embryonic kidney (HEK) 293T cells (ATCC CRL-3216, 
USA). In brief, cells were grown at 37°C with 5% CO2 in 
Dulbecco’s Modified Eagle medium (DMEM, Gibco, USA) 
supplemented with 10% heat-inactivated fetal bovine se-
rum (FBS, Gibco), 100 U/ml penicillin, 100 µg/ml strepto-
mycin and 0.25 µg/ml of amphotericin B. For transfection, 
cells with 80-90% confluency in 100 mm tissue culture 
plates were transfected with purified plasmid DNA using 
polyethylenimine (PEI 87 kDa, Facultad de Farmacia y 
Bioquímica FFyB-UBA, Argentina) in serum-free media. 
The supernatants from transfected cells were harvested 
on day 3-4 post-transfection by centrifugation, and soluble 
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RBD was purified by affinity chromatography on a HisTrap 
HP column (GE Healthcare, UK) following standard pro-
cedures. The eluted pool was dialyzed overnight against 
high salt (300 mM sodium chloride) PBS and concen-
trated to 0.8-1.1 mg/ml. Then, the protein was sterilized 
by filtration and stored at 2-8 °C until use. We reached 
a yield of about 7.5 mg per liter of culture, as estimated 
by measuring its absorbance at 280 nm and by reducing 
SDS-PAGE stained with Coomassie blue. The purity of 
the recombinant protein was checked by SDS-PAGE 
in both reducing and non-reducing conditions (Fig. 1B) 
and by analytical size exclusion chromatography (data 
not shown). A single predominant band was observed at 
approximately 32 kDa under reducing conditions (corre-
sponding to the expected molecular weight of the protein 
[26 kDa] plus glycosylation). The presence of RBD dimers 
under non-reducing conditions is worth to mention3, 11. 
A previous work showed that recombinant RBD can 
elicit strong reactivity and seroneutralization activities in 
mice and horses3. We designed our immunization protocol 
based on this study but using a smaller amount of RBD. 
Explicitly, we used approximately ten times less protein 
than in the referred work, and obtained similar or even 
higher responses, as measured by ELISA using RBD as 
an antigen (Fig. 2A). 
In order to measure the antibody response elicited by 
the immunized horses at different times post immunization, 
we performed an indirect ELISA using purified RBD as an 
antigen. In brief, 96-well plates (Nunc, Merck, USA) were 
coated with 0.25 µg per well of RBD in PBS overnight at 
2-8 °C.  The blocking solution was 3% non-fat milk pre-
pared in PBS with 0.1% Tween 20 (TPBS). To calculate 
the horse serum titers, two-fold serial dilutions of horse 
serum samples prepared in 1% non-fat milk in TPBS were 
added to the plates and incubated at 37 °C for 1 h. Horse-
radish peroxidase-conjugated goat anti-horse F(ab´)2 
(Sigma, Germany) diluted 10 000-fold and substrate 
tetramethylbenzidine solution (Abcam, UK) were used 
for detection. Values of absorbance at 450 nm greater 
than twice those of the negative controls were considered 
as positive. As shown in Figure 2A, we obtained strong 
antibody responses using 1 mg of RBD for each of three 
repeated immunizations (on days 0, 14 and 23) and 0.5 
mg for the final boost (on day 28), compared with 3, 6 and 
12 mg used in the previous report3. 
In parallel with the ELISA assay, we analyzed the in 
vitro neutralization capacity of horse sera using a se-
roneutralization assay against SARS-CoV-2. In brief, a 
SARS-CoV-2 strain was isolated from a clinical specimen 
of a COVID-19 confirmed Argentinean patient. For the 
assay, Vero cells were seeded in 96-well plates with 1.5 
× 104 cells/well overnight. Horse sera were firstly diluted 
in 2% fetal bovine serum-Dulbecco’s modified Eagle’s 
medium supplemented with 1600 U/ml of penicillin, 800 
µg/ml of streptomycin and 10 µg/ml of amphotericin B and 
incubated with 1000 TCID50 (the tissue culture infective 
Fig. 1.– A: Structural model of the interaction between the human ACE2 enzyme (pink) and the viral 
Spike glycoprotein (grey) through its receptor binding domain (RBD, cyan). The interacting region 
is highlighted with a dashed oval. The figure was prepared with PyMOL (Schrödinger, USA) based 
on the Protein Data Bank entries 6VSB16 and 6VW117. B: Analysis of purified RBD by SDS-PAGE. 
From left to right: protein marker (M), RBD in reducing conditions (6 µg, RBD red), and RBD in 
non-reducing conditions (6 µg, RBD non-red)
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dose) of SARS-CoV-2 at 37°C for 1 h. The mixture was 
then added to the cells and incubated at 37 °C for 1 h. The 
cells were washed with PBS and incubated in the same 
medium as before. The cytopathic effect was examined 
for 3 days post-infection. The complete absence of cyto-
pathic effect in an individual culture well was defined as 
protection. This assay showed that horse hyperimmune 
sera reached very high neutralizing titers after the second 
immunization, with values of 1:10 240 that were remark-
ably conserved after the manufacture of the final product, 
as explained below (Fig. 2B).  
As the ELISA reactivity reached a plateau after the 
third immunization with a high neutralizing potency, we 
decided to collect plasma from two horses at day 34 of 
the immunization plan. In order to obtain the first clinical 
batch, the plasma was digested with pepsin under con-
trolled conditions rendering F(ab´)2 fragments from the im-
munoglobulin molecules. The fragments were then further 
purified by salting out and membrane Q chromatography. 
The bulk solution was nanofiltered (20 nm), then sterilized 
through a 0.2 µm pore cartridge and filled in sterile glass 
vials. The total protein content in the final product was 
adjusted to 30 mg/ml. The first batch was released using 
the same good manufacturing practice standard used for 
other equine hyperimmune sera produced at the Instituto 
Biológico Argentino. 
As previously mentioned, a similar strategy was fol-
lowed during the production of NEAST, which demon-
strated to be a safe product. From a regulatory point of 
view, health authorities might consider that the obtained 
anti-SARS-CoV-2 F(ab´)2 antisera should be similar to 
NEAST, since both products only differ in their specificities. 
Besides, the safety of this type of products has been exten-
sively demonstrated12. Thus, it can be considered that, as 
both products were manufactured using the same platform 
and have similar compositions, under the circumstances 
of a pandemic, the anti-SARS-CoV-2 F(ab´)2 antisera can 
advance promptly to a phase 2/3 clinical trial, allowing the 
rapid use of this product during this emergency. 
Notably, the results indicated that our product has 
a high neutralizing capacity against SARS-CoV-2, as 
previously observed3. Recent studies on the potential 
therapeutic use of convalescent human plasma indicate 
highly variable neutralizing responses among individuals, 
with an average geometric mean of 1:2003, 8, 13, 14. Thus, 
with titers of 1:10 240, the obtained horse hyperimmune 
Fig. 2.– A: Horse sera antibody (Ab) titers measured by ELISA. Horses were initially immunized with 1 
mg RBD with complete Freund’s adjuvant via intramuscular injection, and then boosted with 1 mg 
RBD on the second and third immunization with incomplete Freund’s adjuvant each time. Plasma 
was collected on days 7, 14, 23, 28 and 35 after the first immunization for monitoring antibody 
response. For comparison, the Ab titer from the F(ab’)2 fragments product was determined on day 
42. ELISA Ab titers were determined as the dilution of Ab at which the OD ratio (mean value of the 
OD at 450 nm of three individual measurements divided by the OD on day 0) was between 1.8-2.2. 
B: Horse sera neutralizing Ab titers were determined by seroneutralization assays from a pool of 
two horse sera samples on days 14, 28, and 35, and from the F(ab’)2 fragments product on day 42.
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sera bear around 50 times stronger neutralizing capacity 
than the average neutralizing capacity shown by conva-
lescent plasma. 
Since neutralizing antibodies should block the internal-
ization of SARS-CoV-2 to lung cells, it has been postulated 
that their passive administration should render maximal 
clinical benefits if they are applied at early stages of the 
disease. Several clinical studies suggest that convalescent 
plasma therapy applied to critical patients in intensive care 
unit have only limited effects7, 15. However, the limited avail-
ability of convalescent plasma, turns the application of this 
therapy to more patients at early stages a real challenge. 
Since EpAbs do not have this limitation, our clinical plan is 
to apply our hyperimmune serum to patients with moderate 
to severe disease according to the published COVID-19 
Treatment Guidelines (https://covid19treatmentguideli-
nes.nih.gov/) with less than 10 days from the onset of 
symptoms. We anticipate that the clinical trial might begin 
at early July 2020. Should this clinical trial evidence the 
efficacy of the therapy by improving patient outcome, 
we have the potential to scale up the anti-SARS-CoV-2 
hyperimmune serum production for extensive clinical ap-
plication in the current epidemiological situation. 
In conclusion, in this work we show that RBD-immu-
nized horses elicit a large amount of anti-SARS-CoV-2 
neutralizing antibodies, which are capable of neutralizing 
in vitro the virus with around 50 times more potency than 
the average neutralizing capacity shown by convalescent 
plasma. We have produced F(ab´)2 polyclonal antibodies 
that proved to have equally high neutralizing capacity and 
will test them in the next weeks for their efficacy as pas-
sive immunotherapy in patients undergoing early stages 
of the disease. Besides, the safety profile of this type of 
sera is well known and our antibodies are devoid of the 
Fc domain, which averts potential triggering of antibody 
dependent enhancement or cytokine storms. All of this 
reinforces the idea that our therapeutic strategy will play 
a preponderant role in COVID-19 management until an 
effective vaccine is developed.
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